Asthma is regarded as an inflammatory disease of the respiratory tract. Arachidonic acid released from membrane phospholipids by phospholipase A 2 is converted to various metabolites that play important roles in asthma 2) : thromboxane A 2 (TXA 2 ) is produced from arachidonic acid through the cyclooxygenase pathway and leukotrienes (LTs) are synthesized through the 5-lipoxygenase pathway. TXA 2 and LTD 4 are considered to be aggravating factors in asthma with TXA 2 inducing bronchial hyperreactivity and bronchoconstriction, 3, 4) and LTD 4 inducing potent bronchoconstriction, enhanced vascular permeability and mucus secretion. 5, 6) In addition, the levels of TXA 2 and LTs in the plasma, bronchoalveolar lavage fluid (BALF) and urine from patients with bronchial asthma have been shown to be elevated. 7) Based on these observations, TXA 2 and LTD 4 are thought to be potential targets for anti-asthmatic drugs: in fact, highly potent and selective antagonists for these mediators have been used for treatment of asthma.
: thromboxane A 2 (TXA 2 ) is produced from arachidonic acid through the cyclooxygenase pathway and leukotrienes (LTs) are synthesized through the 5-lipoxygenase pathway. TXA 2 and LTD 4 are considered to be aggravating factors in asthma with TXA 2 inducing bronchial hyperreactivity and bronchoconstriction, 3, 4) and LTD 4 inducing potent bronchoconstriction, enhanced vascular permeability and mucus secretion. 5, 6) In addition, the levels of TXA 2 and LTs in the plasma, bronchoalveolar lavage fluid (BALF) and urine from patients with bronchial asthma have been shown to be elevated. 7) Based on these observations, TXA 2 and LTD 4 are thought to be potential targets for anti-asthmatic drugs: in fact, highly potent and selective antagonists for these mediators have been used for treatment of asthma. [8] [9] [10] However, TXA 2 and LTD 4 play different roles in the symptoms of asthma, and clinical trial results of TXA 2 receptor antagonists [11] [12] [13] and LTD 4 receptor antagonists 14, 15) suggest that the predominant mediator varies from patient to patient. These results suggest that an antagonist for both TXA 2 and LTD 4 receptors would be more effective in the treatment of asthma, compared to the selective antagonists. Some TXA 2 and LTD 4 dual receptor antagonists, such as RS-601 16) and YM-158, [17] [18] [19] [20] [21] [22] have been reported to have potent efficacy in various antiasthmatic models.
Based on the above, we planned to design a novel dual antagonist for the TXA 2 and LTD 4 receptors. The potent and selective LTD 4 antagonist montelukast 23) contains a lipophilic chloroquinolylvinyl group and a carboxyl group, whereas the potent and selective TXA 2 antagonist daltroban 24) is a chlorobenzenesulfonamide that also contains a carboxyl group. Since both montelukast and daltroban have a carboxyl group, the TXA 2 and LTD 4 receptor dual antagonists were designed by introducing the chlorobenzenesulfonamide group of daltroban into the structure of montelukast (Fig. 1) . In this report, we describe the structure-activity relationships of TXA 2 and LTD 4 receptor dual antagonists and the pharmacological profiles of selected inhibitors.
Chemistry A series of the 4-chlorobenzensulfonamide propyl derivatives 7a-h was synthesized using the procedure shown in Chart 1. The allylic alcohol 1 25) was oxidized by manganese dioxide to afford the a,b-unsaturated ketone 2. Michael addition of chlorobenzenesulfonamide to compound 2 gave the sulfonamide 3, and the carbonyl group of compound 3 was reduced by sodium borohydride to afford the alcohol derivative 4, which was treated with thionylchloride to give the benzyl chloride 5. Thioalkylation of compound 5 with various thiols gave the esters 6a-h, which were hydrolyzed to afford compounds 7a-h.
A series of benzenesulfonamide ethyl derivatives 18a-j was synthesized using the procedure shown in Chart 2. Condensation of the 7-chloro-2-methylquinoline 8 26) and methyl 3-formylbenzoate in the presence of acetic anhydride gave the ester 9, which was hydrolyzed to afford the benzoic acid derivative 10. Compound 10 was reacted with ethyl isocyanoacetate in the presence of diphenylphosphoryl azide (DPPA) to afford the oxazole derivative 11, which was treated with hydrochloric acid to give the aminoketone derivative 12, followed by the reduction with sodium borohydride to afford the aminoalcohol 13. The amino group of compound 13 was protected with phthalic anhydride, and the resulting phthalimide derivative was treated with methanesulfonyl chloride to give the mesylate 15, which was reacted with various thiols to give the sulfides 16a-f. Compounds 16a-f were treated with methylhydrazine, and the resulting amines were reacted with various sulfonyl chlorides. The resulting esters 17a-j were hydrolyzed to give compounds 18a-j.
A Novel Dual Antagonist of Thromboxane

Results and Discussion
The inhibitory activities of compounds 7a-h and 18a-j against U46619-induced aggregation in guinea pig platelets and against LTD 4 -induced contraction in guinea pig ileum were evaluated, and the results are listed in Table 1 .
Among the 4-chlorobenzenesulfonamide propyl derivatives, the compound possessing an acetic acid group on the sulfur atom (7a) showed no TXA 2 antagonist activity. Replacement of the acetic acid group (7a) with propanoic acid group (7b) or butanoic acid group (7c) enhanced the TXA 2 antagonistic activity, and derivative 7c showed particularly potent TXA 2 antagonist activity with an IC 50 value of 150 nM. The introduction of 3,3-dimethyl (7d) or dimethylene (7e) groups on the butanoic acid reduced the TXA 2 antagonist activity, with IC 50 values of 1100 nM and 500 nM, respectively. Replacement of butanoic acid (7c) on the sulfur atom with 4-carboxyphenylmethyl (7f), 4-carboxymethylphenylmethyl (7g) or 2-(4-carboxyphenyl)ethyl (7h) groups reduced the TXA 2 inhibitory activity compared with compound 7c. Introduction of a phenyl ring or bulky substituent between the sulfur atom and the carboxylic acid group were unfavorable for TXA 2 antagonist activity.
Among the 4-chlorobenzenesulfonamide ethyl derivatives 18a-f, the compounds possessing propanoic acid (18a), 3,3-dimethylbutanoic acid (18b) and 3,3-dimethylenebutanoic acid (18c) on the sulfur atom showed less potent TXA 2 antagonist activities than that of daltroban. On the contrary, the compounds with 4-carboxyphenylmethyl (18d) and 2-(4-carboxyphenyl)ethyl (18f) groups on the sulfur atom showed potent TXA 2 antagonistic activities with IC 50 values of 340 nM and 510 nM, respectively. The compound with a 4-carbonylmethylphenylmethyl group (18e) on the sulfur atom showed reduced TXA 2 antagonistic activity, compared with compound 18d. In the 4-chlorobenzenesulfonamide ethyl derivatives, introduction of a phenyl ring on the sulfur atom was favorable for TXA 2 antagonist activity.
Next, we investigated the influence of the substituent on the 4-position of the benzene sulfonamide group on TXA 2 antagonistic activity. Removal of the chloro group (18g) caused loss of activity. The bromo derivative 18h was almost as potent as the chloro derivative 18d, but the nitro (18i) and fluoro (18j) derivatives showed decreased TXA 2 antagonist activity. From these results, it was concluded that the nature of the substituents on the 4-position of the benzene sulfonamide group are important for TXA 2 antagonistic activity.
As shown in Table 1 , montelukast has potent LTD 4 antagonistic activity with an IC 50 value of 0.085 nM. In the series of 4-chlorobenzenesulfonamide propyl derivatives, the influence of the length of the methylene chain on the sulfur atom (7a-c) on the LTD 4 antagonistic activity differed from that for TXA 2 antagonistic activity. The compound with a propanoic acid group on the sulfur atom (7b) showed potent LTD 4 antagonist activity, with an IC 50 value of 0.41 nM. Replacement of the propanoic acid group in compound 7b with acetic acid (7a) or butanoic acid (7c) resulted in a decrease in the LTD 4 antagonistic activity. Compounds with dimethyl (7d) or dimethylene (7e) groups at the 3 position of the butanoic acid group in compound 7c retained potent LTD 4 antagonist activities, with IC 50 values of 0.41 and 0.21 nm, respectively. These results suggest that a bulky substituent at the 3 position of the butanoic acid group in compound 7c is tolerated for LTD 4 antagonistic activity. Replacement of the propanoic acid group of compound 7b with 4-carboxyphenylmethyl (7f), 4-carboxymethylphenylmethyl (7g) or 4-carboxyphenylethyl (7h) groups resulted in a decrease in LTD 4 antagonist activity suggesting that a phenyl group in this position causes a loss of this activity.
Among the 4-chlorobenzenesulfonamide ethyl derivatives, the compound with a 2-propanoic acid group (18a) on the sulfur atom showed LTD 4 antagonist activity, with an IC 50 value of 1.7 nM. Replacement of the carboxyethyl group in compound 18a with 3,3-dimethylbuanoic acid (18b) or 3,3-dimethylenebutanoic acid (18c) groups on the sulfur atom increased the LTD 4 antagonist activity, with IC 50 values of 0.24 nM and 0.23 nM, respectively. These results suggest that bulky substituents on the butanoic acid in compound 18a are favorable for LTD 4 antagonist activity. Replacement of the propanoic acid group in compound 18a with a carboxyphenylmethyl group (18d) resulted in an increase in this activity, with an IC 50 value of 0.40 nM. The compounds with carboxymethylphenylmethyl (18e) or carboxyphenylethyl (18f) groups showed less potent LTD 4 antagonist activity compared to compound 18d, with IC 50 values of 2.1 nM and 3.0 nM, respectively. These results suggest that the distance between the sulfur atom and the carboxylic acid group is important for potent LTD 4 antagonist activity. Removal (18g) or replacement of the chloro group at the 4-position of the benzenesulfonamide group in compound 18d with bromo (18h), nitro (18i) or fluoro (18j) groups increased the LTD 4 antagonistic activity, with IC 50 values of 0.041 nM, 0.077 nM, 0.23 nM and 0.12 nM, respectively. These results suggest that substituents on the benzenesulfonamide group do not significantly influence the activity.
Selected compounds (7c, 7e, 18d, 18g, 18h, 18j) which possessed potent TXA 2 and LTD 4 antagonist activities were tested for their ability to inhibit the LTD 4 -induced acceleration of plasma leakage to skin and U46619-induced increase in airway resistance in guinea pig after oral administration. The results are shown in Table 2 . Compounds 7e and 18d showed potent inhibition of LTD 4 -induced acceleration of plasma leakage, with ED 50 values of 0.12 and 0.47 mg/kg, respectively. Compound 18d also showed inhibitory activity against the U46619-induced increase in airway resistance with an ED 50 value of 3.3 mg/kg. Compound 7e was less potent than compound 18d in this respect.
In conclusion, in order to find an orally active TXA 2 and LTD 4 dual antagonist, we designed and synthesized chloroquinolylvinylphenyl derivatives based on the molecular structures of the TXA 2 antagonist daltroban and the LTD 4 antagonist montelukast. Among these compounds, 18d showed potent TXA 2 and LTD 4 antagonist activity both in vitro and in vivo.
Experimental
1 H-NMR spectra were obtained on a JEOL JNM-EX90 or JNM-A500 spectrometer and chemical shifts are expressed as d (ppm) values with tetramethylsilane as the internal standard. Abbreviations of the 1 H-NMR signal patterns are as follows: s, singlet; d, doublet; dd, double doublet; t, triplet; q, quartet; m, multiplet: br, broad. Mass spectra were obtained on a JEOL JMS-DX300 or Hitachi M-80 spectrometer. Column chromatography on silica gel was performed with Wakogel C-200. Preparative thin-layer chromatography was performed with Merck PLC plate Silica gel 60 F 254 .
1-{3-[(E)-2-(7-Chloro-2-quinolyl)vinyl]phenyl}propenone (2)
A mixture of 1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}propenol (26.2 g, 81.4 mmol), manganese dioxide (131 g, 1.51 mol) and toluene (500 ml) was refluxed for 3 h. The reaction mixture was cooled to room temperature and then filtered through celite. The filtrate was evaporated in vacuo. Column chromatography of the residue on silica gel (AcOEt : CHCl 3 :
n-hexaneϭ3 : 30 : 70) gave 2 (10.6 g, 41%) as a colorless solid. 
4-Chloro-N-(3-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}-3-oxopropyl)benzenesulfonamide (3)
A mixture of 2 (8.70 g, 27.2 mmol), 4-chlorobenzenesulfonamide (5.73 g, 29.9 mmol), potassium tert-butoxide (0.10 g, 0.89 mmol), 1,4-dioxane (80 ml) and benzene (80 ml) was stirred at 80°C for 10 h. The reaction mixture was evaporated in vacuo. Column chromatography of the residue on silica gel (0.2% MeOH-CHCl 3 ) gave 3 (8.10 g, 58%) as a colorless solid. 
(؎)-4-Chloro-N-(3-chloro-3-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]-phenyl}propyl)benzenesulfonamide (5)
A solution of 4 (8.40 g, 16.4 mmol) in 1,2-dichloroethane was combined with thionyl chloride (1.43 ml, 19.6 mmol) at 5°C. The reaction mixture was stirred at room temperature for 5 h, and then ice and saturated aqueous sodium bicarbonate solution were added. The reaction mixture was extracted with CHCl 3 , washed with brine, dried over Na 2 SO 4 , and evaporated in vacuo. Column chromatography of the residue on silica gel (AcOEt : n-hexaneϭ1 : 4→3 : 7) gave 5 (8.52 g, quant.) as a yellow amorphous solid. 4-{[(3-{4-Chlorophenylsulfonylamino}-1-{3-[(E)-2-(7-chloro-2-quinolyl) 
Methyl 3-[(E)-2-(7-Chloro-2-quinolyl)vinyl]benzoate (9)
A mixture of 7-chloroquinaldine (8, 5.40 g, 30.4 mmol), methyl isophthalaldehyde (5.99 g, 36.5 mmol) and acetic anhydride (8.61 ml, 91.2 mmol) in xylene (54 ml) was stirred under reflux for 8 h. The reaction mixture was cooled to room temperature, and the solvent was evaporated under reduced pressure. Diethylether was added to the residue and the resulting precipitate was collected by filtration to give 9 (4.65 g) as a colorless solid. 
3-[(E)-2-(7-Chloro-2-quinolyl)vinyl]benzoic Acid (10)
A mixture of 9 (4.60 g, 14.2 mmol), tetrahydrofurane (46 ml) and methanol (23 ml) was combined with aqueous 1 M NaOH solution (21 ml) and stirred at 40°C. for 3 h. The reaction mixture was acidified with an aqueous 10% citric acid solution and the resulting precipitate was collected by filtration to give 10 as a colorless solid. 
Ethyl 5-{3-[(E)-2-(7-Chloro-2-quinolyl)vinyl]phenyl}oxazol-4-carboxylate (11)
A solution of 10 (4.70 g, 15.2 mmol) in dimethylformamide (70 ml) was combined with potassium carbonate, 1.5 hydrate (5.01 g, 30.3 mmol) and ethyl isocyanoacetate (2.23 g, 19.7 mmol), and then stirred for 5 min. at room temperature. Diphenylphosphoryl azide (5.01 g, 18.2 mmol) was added to the reaction mixture at 5°C, and the mixture was stirred for 20 h at room temperature. Ice-water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed with water and brine, dried over MgSO 4 , and evaporated in vacuo. Column chromatography of the residue on silica gel (5% ethyl acetate-CHCl 3 ) gave 11 (5.01 g, 93%) as a colorless solid. 
2-Amino-1-{3-[(E)-2-(7-chloro-2-quinolyl)vinyl]phenyl}ethanone Dihydrochloride (12)
A mixture of 11 (5.00 g, 12.4 mmol), ethanol (25 ml) and concentrated HCl (25 ml) was stirred under reflux for 6 h. The reaction mixture was cooled to room temperature, and the resulting precipitate was collected by filtration to give 12 (4.80 g, 98%) as a colorless solid. 
(؎)-N-(2-{3-[(E)-2-(7-Chloro-2-quinolyl)vinyl]phenyl}-2-hydroxyethyl)phthalimide (14)
A mixture of 13 (16.10 g, 49.6 mmol), phthalic anhydride (7.34 g, 49.6 mmol) and toluene (20 ml) was stirred and heated to 160°C, and then stirred under reduced pressure (3 mmHg) for 3 h. The reaction mixture was cooled to room temperature, and then acetonitrile was added. The resulting precipitate was collected by filtration to give 14 (18.8 
(؎)-1-{3-[(E)-2-(7-Chloro-2-quinolyl)vinyl]phenyl}-2-phthalimidoethylmethanesulfonate (15)
An ice-cold mixture of 14 (17.8 g, 39.1 mmol), pyridine (53 ml) and 1,2-dichloroethane was combined with methanesulfonylchloride (3.36 ml, 47.0 mmol), and the mixture was stirred at room temperature for 12 h. The reaction mixture was acidified with 10% aqueous solution of citric acid, and then the mixture was extracted with CHCl 3 . The organic layer was washed with a 10% aqueous solution of citric acid, a 5% aqueous solution of potassium carbonate and brine, dried over MgSO 4 , and evaporated in vacuo. The residue was combined with acetonitrile, and the resulting precipitate was collected by filtration to give 15 (19.0 g) as a colorless solid. 
(؎)-Methyl 4-{[(1-{3-[(E)-2-(7-Chloro-2-quinolyl)vinyl]phenyl}-2-phthalimidoethyl)thio]methyl}benzoate (16d)
A mixture of 15 (3.00 g, 5.6 mmol), methyl 4-mercaptomethylbenzoate (1.54 g, 8.4 mmol) and dimethylsulfoxide (90 ml) was combined with cesium carbonate (3.96 g, 11.3 mmol) at 20°C. The reaction mixture was stirred at room temperature for 1 h, and then benzene, ice and water were added. The reaction mixture was filtered, and the organic layer of the filtrate was washed with water and brine, dried over MgSO 4 , and evaporated in vacuo. Column chromatography of the residue on silica gel (benzene→5% AcOEt-benzene) gave 16d (1.54 g) as a colorless solid. Methyl 4-{[(1-{3-[(E)-2-(7-Chloro-2-quinolyl)vinyl]phenyl}-2-phthalimidoethyl)thio]-2-ethyl}benzoate (16f) The title compound was prepared from methyl 4-(2-mercaptoethyl)benzoate in the same manner as described above, and obtained as a pale yellow solid. (26%). 50 g, 2.4 mmol) , 1,4-dioxane (10 ml) and ethanol (20 ml) was com-bined with methylhydrazine (1.55 ml, 29.0 mmol), and stirred under reflux for 7 h. The reaction mixture was cooled to room temperature, and then ice and a 5% aqueous solution of potassium carbonate were added. The reaction mixture was extracted with 1,2-dichloroethane, washed with a 5% aqueous solution of potassium carbonate and brine, dried over Na 2 SO 4 and evaporated in vacuo. The residue was dissolved in 1,2-dichloromethane, cooled to 5°C and combined with triethylamine (0.51 ml, 3.6 mmol) and 4-chlorobenzenesulfonyl chloride (0.61 g, 2.9 mmol). The reaction mixture was stirred for 12 h at 5°C, and then acidified with a 10% aqueous solution of citric acid. The organic layer was washed with brine, dried over Na 2 SO 4 , and evaporated in vacuo. Column chromatography of the residue on silica gel (3% AcOEt-benzene→5% AcOEt-benzene) gave 17d (1.03 g, 65%) as a colorless solid. 49 mmol), tetrahydrofuran (6 ml) and methanol (3 ml) was combined with a 1 M aqueous solution of NaOH (1.2 ml, 1.2 mmol). The reaction mixture was stirred at room temperature for 12 h, and then acidified with 10% aqueous solution of citric acid. The reaction mixture was extracted with chloroform, washed with brine, dried over MgSO 4 , and evaporated in vacuo. Following column chromatography of the residue on silica gel (AcOEt : nhexaneϭ3 : 7) gave 7b (0.08 g, 27%) as a pale yellow amorphous. The title compound was prepared from 6e in the same manner as de-calculated from the inhibition ratio on the basis of the maximum light transmittance. All experiments were carried out within 4 h after blood collection to avoid a decrease in platelet sensitivity to U46619. LTD 4 -Induced Acceleration of Plasma Leakage in Guinea Pig Skin Male Hartley guinea pigs whose back fur had been shaved with an electric clipper on the day before the experiment were given an intravenous administration of saline (1 ml per animal) containing 1% Evans blue. Two minutes later, 5 ng LTD 4 and the vehicle solution were administered intracutaneously on the back of the guinea pig (at 2 points for LTD 4 and 2 points for vehicle). The guinea pig was sacrificed by decapitation 30 min later. The skin was removed, and the visible blood in the isolated skin was also removed as much as possible. The pigment retained within the skin was then extracted by the addition of extraction buffer ( [7 : 3] acetone : 0.5% Na 2 SO 4 solution) and the amount of LTD 4 -induced pigment leakage was measured using the 620 nm absorbance of the extract (UV-visible spectrophotometer, model UV-160A; Shimadzu, Kyoto). LTD 4 -induced dye leakage was defined by subtracting the dye content in the vehicle-injected site from that in the LTD 4 -induced site, so these calculated dye contents were collected for Evans blue dye remaining within the vasculature. This dye amount was used as an index of plasma leakage, although there was a potential uncontrolled hydrostatic pressure effect in this system. Test compounds were orally administered 1 h before intracutaneous administration of LTD 4 .
U46619-Induced Increase in Airway Resistance Increase Male Hartley guinea pigs were anesthetized by intraperitoneal injection of 1.2 g/kg urethane and a tracheal cannula was inserted. Spontaneous respiration was stopped with gallamine (1 mg/kg i.v.), and artificial respiration was carried out at a rate of 60 strokes/min and a volume of 1 ml/100 g body weight per cycle. After intravenous administration of U46619 (3 mg/kg), airway resistance was measured using a respiratory function measuring apparatus (Model 6; Buxco Electronics, Inc., Sharon, CT, U.S.A.). The airway resistance was measured as the mean of every 5 s and expressed as the percentage change compared with the basal resistance level. The test compound was orally administered 1 h before intravenous injection of agonists. The effects of each compound were evaluated using the peak percentage change in lung resistance.
